anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Severe acute respiratory syndrome coronavirus-2 (SARS-COV-2) infection is well established as a systemic disease including kidney damage. The entry point into the renal cell remains the angiotensin-converting enzyme 2 (ACE-2) receptor and the spectrum of renal lesions is broad, with a clear predominance of structural and functional tubular lesions. The most common form of glomerular injury is collapsing glomerulopathy (CG), which is strongly associated with apolipoprotein L1(APOL-1) risk variants. These acute lesions, which are secondary to the direct or indirect effects of SARS-CoV-2, can progress to chronicity and are specific to long COVID-19 in the absence of any other cause. Residual inflammation associated with SARS-CoV-2 infection, in addition to acute kidney injury (AKI) as a transitional state with or without severe histological lesions, may be responsible for greater kidney function decline in mild-to-moderate COVID-19. This review discusses the evidence for renal histological markers of chronicity in COVID-19 patients and triggers of low-grade inflammation that may explain the decline in kidney function in the post-COVID-19 period.
SLED is a kind of hemodialysis technique performed using Fresenius 4008B dialysis machine with FDX 120 GW (NIKKISO Japan) dialyzer. SLED sessions were 6-8 hour duration, three times per week (except Sunday), In case of severe volume overload, the session could be increased to meet clinical situation. Blood flow was maintained between 150-200 mL/hr and the dialysate flow of 300 mL/hr. Both the groups use unfractionated heparin as anticoagulant to prevent clotting of the extracorporeal circuit .the target partial thromboplastin time( PTT) was not more than twice the control level.
BACKGROUND: Occurrences of weight stigma have been documented in prenatal clinical settings from the perspective of pregnant patients, however little is known from the viewpoint of healthcare providers themselves. Reported experiences of weight stigma caused by maternal healthcare providers may be due to negative attitudes towards obesity in pregnancy and a lack of obesity specific education. The objective of this study was to assess weight-related attitudes and assumptions towards obesity in pregnancy among maternal healthcare providers in order to inform future interventions to mitigate weight stigma in prenatal clinical settings.
METHODS: A cross-sectional survey was administered online for maternal healthcare providers in Canada that assessed weight-related attitudes and assumptions towards lifestyle behaviours in pregnancy for patients who have obesity. Participants indicated their level of agreement on a 5-point likert scale, and mean scores were calculated with higher scores indicating poorer attitudes. Participants reported whether they had observed weight stigma occur in clinical settings. Finally, participants were asked whether or not they had received obesity-specific training, and attitude scores were compared between the two groups.
RESULTS: Seventy-two maternal healthcare providers (midwives, OBGYNs, residents, perinatal nurses, and family physicians) completed the survey, and 79.2% indicated that they had observed pregnant patients with obesity experience weight stigma in a clinical setting. Those who had obesity training perceived that their peers had poorer attitudes (3.7 ± 0.9) than those without training (3.1 ± 0.7; t(70) = 2.23, p = 0.029, Cohen's d = 0.86).
CONCLUSIONS: Weight stigma occurs in prenatal clinical environments, and this was confirmed by maternal healthcare providers themselves. These findings support advocacy efforts to integrate weight stigma related content and mitigation strategies in medical education for health professionals, including maternal healthcare providers. Future work should include prospective examination of weight related attitudes among maternal healthcare providers and implications of obesity specific education, including strategies on mitigating weight stigma in the delivery of prenatal care.
This study introduces a novel approach of repetitive modeling to simulate the pathological process of recurrent gout attacks in humans. This methodology addresses the instability issues present in rat models of gout, providing a more accurate representation of the damage recurrent gout episodes inflict on human skeletal systems. A soluble nanoneedle system encapsulating colchicine and iguratimod ethosomal formulations was developed. This system aims to modulate inflammatory cytokines and inhibit osteoclast activity, thereby treating inflammatory pain and bone damage associated with recurrent gout. Additionally, a comprehensive evaluation of the microneedles' appearance, morphology, mechanical properties, and penetration capability confirmed their effectiveness in penetrating the stratum corneum. Dissolution tests and skin irritation assessments demonstrated that these microneedles dissolve rapidly without irritating the skin. In vitro permeation studies indicated that transdermal drug delivery via these microneedles is more efficient and incurs lower drug loss compared to traditional topical applications. In vivo pharmacodynamic assessments conducted in animal models revealed significant analgesic and anti-inflammatory effects when both types of microneedles were used together. Further analyses, including X-ray imaging, hematoxylin and eosin (H&E) staining, Safranin-O/fast green staining, tartrate-resistant acid phosphatase staining, and quantification of osteoclasts, confirmed the bone-protective effects of the microneedle combination. In conclusion, the findings of this research underscore the potential of this novel therapeutic approach for clinical application in the treatment of recurrent gout.
It consisted of 30 participants diagnosed as having diabetic peripheral neuropathy. Each received traditional balance exercise, resistance exercise, and whole-body vibration, for 6 weeks.
A disinfectant or dentifrice comprises a soluble sulphocyanide treated with a protecting substance for nullifying its hygroscopic properties, and a solid water soluble acid substance such as an acid or acid salt.  The added protective substance should be such as will not impair substantially the solubility of the sulphocyanide.  It may also be added to the acid component before admixture with the sulphocyanide.  Suitable protective substances are tragacanth, gelatine, albumin, dextrin, saponin, and the like, to which a suitable hardening agent may sometimes be added, e.g. formaldehyde, tannic acid.  Gypsum is also suitable as a protective agent. Alkaline substances may also be added, e.g. borax, carbonates or bicarbonates and these are rendered sufficiently difficultly soluble by a coating substance such as resin to enable the sulphocyanic acid to become effective before recombination with the alkaline substance. Suitable acid substances for effecting the decomposition of the sulphocyanide are tartaric, citric, boric acids and potassium bisulphate.  The components may be separately granulated with the protective agents and then mixed.  Carbonates are effective additions to dentifrices and powders for mouth washes &c. and may be mixed with the sulphocyanide and a protective agent before admixture with the acid, which in this case will be in quantity sufficient to react with both the other components.  The mixtures may have a polishing agent added to produce a dentifrice.  They may be formed into tablets &c. or converted into a paste by admixture with a liquid in which the substances are insoluble.  According to an example a mixture of calcium sulphocyanide, saponin, and saccharine is dissolved in water and the solution stirred with sufficient gypsum to produce a slightly moist mass which is dried at 70-80 DEG  C. Tartaric acid is mixed with tragacanth and a small quantity of alcohol stirred into the mixture, the mass being then dried.  The two components are then intimately mixed.
Taper from current antidepressant therapy. Start bupropion once-daily extended, titrated from 150-300 mg daily based on symptom severity and side effects.
Solid or semi-solid compositions containing dispersed methyl cellulose or methyl hydroxy-ethyl cellulose are prepared by mixing together dehydrated calcium lactate, a quantity of water greater than that required to rehydrate the lactate, and the cellulose derivative to be dispersed, or by heating a mixture of hydrated calcium lactate and water, for instance to 90 DEG  or 100 DEG  C., and incorporating the cellulose derivative into the mixture at any stage.  In an example, a 4 per cent aqueous dispersion of methyl hydroxyethyl cellulose, water and dehydrated calcium lactate are mixed together to give a stiff paste.ALSO:A solid or semi-solid detergent composition is made by mixing together dehydrated calcium lactate, a quantity of water greater than that required to rehydrate the lactate and a detergent, or by heating a mixture of hydrated calcium lactate and water, for instance to 90 or 100 DEG  C., and incorporating the detergent into the mixture at any stage.  The latter method may take the form of adding hydrated calcium lactate to a heated aqueous solution containing the detergent.  The detergent may be soap or a synthetic detergent, or a mixture of both.  Synthetic detergents specified are those sold under the Registered Trade Marks "Teepol," "Empicol L.Z." and "Lorol," and long-chain alkyl sulphates and sulphonates in general.  Such compositions may also contain liquid paraffin, mineral oils, waxes such as the polyethylene glycol wax sold under the Registered Trade Mark "Carbowax," glycerol, sorbitol, mannitol, erythritol, polyvinyl alcohol, triethanolamine, stearic acid, lactic acid, sodium sulphate, calcium chloride, magnesium chloride, sodium lactate, starch, gum tragacanth, methyl cellulose, and "Tylose" (Registered Trade Mark).  The compositions may be formed into tablets, blocks, flakes, powders or pastes.  In an example, sulphonated "Lorol," glycerine, gum tragacanth, anhydrous calcium lactate and water are mixed together, the composition hardening during the mixing operation to give a solid detergent cake.  In another example calcium lactate (5H2O) and water are heated at 95 DEG C. until solution is complete; starch is then added, followed by "Teepol" in powder form, and the mixture is allowed to cool, whereupon it forms a hard solid mass.ALSO:Solid or semi-solid compositions useful as bases in the formulation of cosmetic creams are made by mixing together dehydrated calcium lactate, a quantity of water greater than that required to rehydrate the lactate, and a substance to be dispersed such as liquid paraffin or methyl hydroxyethyl cellulose.  Alternatively, a mixture of hydrated calcium lactate and water may be heated, for instance to 90 or 100 DEG C., and the substance to be dispersed incorporated into the mixture at any p  stage.  In an example dehydrated calcium lactate, liquid paraffin and water are mixed together.  The composition sets to a lard-like mass in 24 hours.  In a further example, a 4 per cent. aqueous dispersion of methyl hydroxyethyl cellulose, water and dehydrated calcium lactate are mixed together to give a stiff lard-like paste.
Headache is the most frequent side effect and was the cause of 2% of all dropouts from controlled-clinical trials. Headache decreased in incidence after the first few days of therapy.

The following table shows the frequency of adverse reactions observed in 1% or more of subjects in 6 placebo-controlled trials, conducted in the United States and abroad. The same table shows the frequency of withdrawal for these adverse reactions. In many cases the adverse reactions were of uncertain relation to drug treatment.

Other adverse reactions, each reported by fewer than 1% of exposed patients, and in many cases of uncertain relation to drug treatment, were:

Extremely rarely, ordinary doses of organic nitrates have caused methemoglobinemia in normal-seeming patients; for further discussion of its diagnosis and treatment see Overdosage.
Participants will receive matching placebo orally once a day for 14 weeks in Period 1. In Period 2 participants will receive 15 mg upadacitinib orally once a day for 90 weeks.
All study participants will receive the same treatment. Each participant will be given intravenous, which means by vein (IV), vitamin C three times a day for 14 days. Then participants will take vitamin C orally (by mouth in pill form) twice a day each day until 6 months after transplant. The treatment is IV vitamin C 50 mg/kg/day. After completion of the IV vitamin C doses, oral vitamin C 500 mg twice each day.
PURPOSE:To improve the formability and the tensile adhesive property of an apatite cover in restoring a bone, by kneading a mixture of tricalcium diphosphate and tetracalcium oxide diphosphate in water and then applying the mixture onto a metal or ceramic base to form the apatite cover. CONSTITUTION:A mixture of tricalcium diphosphate [alpha-Ca3(PO4)2] and tetracalcium oxide diphosphate [Ca4O(PO4)2] is kneaded in water or an aqueous solution containing at least one acid or salt, is applied onto a metal or ceramic base and is then cured by hydration to form an apatite cover. The mixture of tricalcium diphosphate and tetracalcium oxide diphosphate is prepared by dehydrating and thermally decomposing a hydroxyapatite at a high temperature of 1,350 deg.C or higher and then by grinding it. The hydroxyapatite used contains calcium and phosphorous in the molar ratio of 1.66-1.68:1. Preferably, the apatite cover formed is further hydrothermally treated in a high-pressure steam reaction tank. When the apatite cover is heat-treated in a temperature range of 50-1,300 deg.C, the adhesive property thereof can be improved.
Fibrosis is characterized by scarring and hardening of tissues and organs. It can affect every organ system, and so could result in organ failure due to the accumulation of extracellular matrix proteins. Previous studies suggest that mechanical forces (such as shockwave therapy, SWT) initiate a process of mechanotransduction and thus could regulate fibrosis. Nevertheless, it is largely unexamined which pathways are exactly involved in the application of SWT and can regulate fibrosis. The present article seeks to elucidate the underlying effect of SWT on fibrosis. Evidence shows that SWT activates macrophage activity, fibroblast activity, collagen amount and orientation and apoptosis, which ultimately lead to an adaptation of inflammation, proliferation, angiogenesis and apoptosis. The included articles reveal that other proteins and pathways can be activated depending on the energy levels and frequency of SWT. These findings demonstrate that SWT has beneficial effects on fibrosis by influencing the proteins and pathways. Based on these data, which highlights the underlying mechanisms, we can make preliminary conclusions about the treatment modalities of SWT in scar formation, such as the energy levels and frequencies that are necessary to prevent or treat fibrotic tissue.
Participants: There will be 130 alcohol-dependent individuals between 18 and 65 years of age recruited to participate in this randomized placebo-controlled clinical trial. Eighty alcohol-dependent individuals will be randomized into the study and we are allowing for 50 screen failures. Participation in this study will be an alternative to standard treatment. Subjects will be blindly assessed for SL/SDL status to yield 50% representation of each trait.

Procedures (methods): Subjects who meet general inclusion/exclusion criteria based on the screening interview will complete a sweet taste assessment. Results, along with craving score, will be given to the Investigational Drug Services for randomization purposes. The study is a double-blind, randomized, placebo-controlled clinical trial in which participants will receive 50 mg oral naltrexone or matching placebo for a 12-week period. In addition participants will meet with a trained therapist for nine 30-minute BRENDA therapy sessions Medical monitoring will also be conducted by study physicians and will consist of review of vital signs, concomitant medication use, and general inquiries into side effects.
Sleep disturbance is common in older adults and is associated with increased healthcare utilization, more depressive symptoms, and other adverse effects on health-related quality of life. Obstructive sleep apnea (OSA) is a disorder characterized by repetitive episodes of complete or partial upper airway obstruction occurring during sleep. OSA increases in prevalence with age, and is associated with increased risk of cardiovascular disease, decreased quality of life, and increased mortality. Insomnia also increases in prevalence with age, and is associated with numerous adverse outcomes, including cognitive decline, decreased quality of life, increased healthcare costs and increased mortality. The diagnostic criteria for insomnia include a decreased ability to fall asleep or stay asleep, frequent nighttime awakening or poor quality sleep that is associated with daytime impairment such as fatigue, impaired attention, or daytime sleepiness. Increasing evidence suggests that insomnia often coexists with OSA, particularly in older adults, and predicts worse outcomes of OSA. Both OSA and insomnia have a higher prevalence among Veterans, compared to the general population.

Little is known of the best approaches to manage the large number of patients with coexisting OSA and comorbid insomnia. Guidelines for best practice typically address these conditions separately, where positive airway pressure (PAP) is the standard for the treatment of OSA, and cognitive behavioral therapy for insomnia (CBT-I) is considered first-line treatment for chronic insomnia. CBT-I is particularly recommended for insomnia in older adults, where adverse effects of sleeping medications are most problematic. Early adherence to PAP therapy (i.e., within the first week of PAP therapy) is one of the strongest predictors of long-term PAP adherence. However, adherence rates to PAP therapy in patients with OSA are low. In addition, CBT-I has not been widely implemented for treatment of insomnia (in part due to limited access to mental health specialists able to provide CBT-I), untreated OSA limits response to treatment of insomnia, and untreated insomnia negatively impacts PAP adherence.

Based on this evidence and findings from the investigators' prior work, the investigators believe that an integrated, behavioral treatment approach which addresses both OSA and insomnia early in the course of PAP therapy is needed to maximize patient adherence and treatment success when these conditions coexist. The investigators propose a randomized controlled trial to test a novel, behavioral approach integrating best practices for management of both conditions among older Veterans with OSA who are prescribed PAP therapy and have comorbid insomnia. The purpose of this project is to determine whether this intervention improves nighttime sleep and PAP adherence.
Secondary surgical repair of the perineal body. Operation is performed by a urogynecologist in an operation theater in local anesthesia. The operation aims to re-create the anatomy in the injured perineum using 2-4 sutures.
This study is an observational study using a longitudinal data collection design with non-invasive measures. Fifty participants who are about to begin the Healthy Lifestyle Program (HLP) at the Weight and Wellness Clinic (WWC) and another 50 participants who are about to complete HLP will be recruited to the study. After informed consent is obtained, the patient will be asked to complete several questionnaires about sleep and wellbeing. Their height and weight will also be measured by the research staff. The patient will then be given a wrist-worn accelerometer to wear for 16 weeks to measure their sleep and physical activity. They will be asked to complete the same set of questions at approximately the 8th and 16th week at a research visit. Data on existing diagnosis of sleep disorders will be extracted from the patients' electronic medical records.
* Hands should be washed after the handling of lidocaine patch 5%, and eye contact with lidocaine patch 5% should be avoided. Do not store patch outside the sealed envelope. Apply immediately after removal from the protective envelope. Fold used patches so that the adhesive side sticks to itself and safely discard used patches or pieces of cut patches where children and pets cannot get to them. Lidocaine patch 5% should be kept out of the reach of children.

Close
A dentifrice comprises a cleansing agent, e.g. soap or borax, an antiseptic, a polishing agent, e.g. calcium carbonate, and a sufficient quantity of wax, e.g. ceresine, to form a thin protective coating on the teeth when brushed regularly with the dentifrice.  A suitable composition consists of sodium perborate, magnesium oxide, sodium bicarbonate, sodium chloride, calcium carbonate, powdered borax, powdered castile soap, ceresine, soluble saccharine, menthol, thymol and flavouring substances. The mixture is compounded with the aid of ether which is then evaporated and the material reduced to powder.
FIELD: medicine. SUBSTANCE: resistance enhancement to hyperthermia is attained in experiment by administration the combination of relanium (5 mg/kg) with sodium hydroxybutyrate (500 mg/kg) 30 min before hyperthermia onset into stomach of white rats by gavage. It is recommended the combined oral administration 10 mg relanium with 2 g sodium hydroxybutyrate before hyperthermia onset. Seduxen (Hungary) or sibazon (Russia) can be used instead of relanium (Poland) as its pharmacoanalogs. A single dose of relanium and its pharmacoanalogs can be at therapeutic range from 5 to 20 mg. Sodium hydroxybutyrate can be replaced for lithium hydroxybutyrate at the same dose, i. e. 2 g orally. Proposed agent enhances organism resistance to hyperthermia due its effect on the central nervous and cardiovascular systems rather then due to heat limitation input in organism from external sources as in the case of heat-protective outfit use. EFFECT: increased effectiveness of agent.
This cohort will include 3 patients with the first calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity (DLT) in this group the study continues including the next cohort. However, if If only one patient in a given cohort develops DLT, three more patients will be included at that dose level, up to a maximum total of six patients per dose level. If two or more of the three patients of a certain dose level develop DLT, this dose level is considered very toxic, and the study does not proceed. If this occurs at the first dose level, the study will be finalized. If only one in six patients at a dose level develops DLTs, escalation proceeds until Tolerated Maximum Dose.
<P>PROBLEM TO BE SOLVED: To provide a method and an apparatus for photochemically inactivating pathogens by batchwise irradiation.  <P>SOLUTION: An effective method for determining effective dose for inactivating pathogens in a fluid sample is described. In particular, the invention covers methods for determining a photochemically effective dose sufficient to inactivate pathogens in a biological sample, while leaving biologically active materials of interest unaffected. The method includes a process for irradiating the above described biological fluid by monochromatic or polychromatic effective dose from one or more light sources. A batchwise reaction vessel effective for inactivating pathogens in the biological sample is also described.  <P>COPYRIGHT: (C)2010,JPO&INPIT